Strangvac® clinical trials confirm expected efficacy
Efficacy – Onset of immunity
Efficacy – Duration of immunity
Strangvac® vaccination reduced the amount of clinical disease at two months post basic vaccination.
Efficacy – Onset of immunity following re-vaccination
Strangvac® conferred excellent levels of protection against challenge with S. equi two weeks post re-vaccination.
Strangvac® has DIVA capability, which will be invaluable for the use of this vaccine in populations of horses where infection with S. equi is endemic.
Strangvac® will play a significant role in the prevention of Strangles in horses, in particular through the re-vaccination of horses following the identification of an index case or prior to the transportation of an animal to equine events where there is a risk of exposure to S. equi.
Intervacc CEO, Jan-Ingmar Flock, comments that it is with great pleasure that we now have been able to get the results from the final studies at Animal Health Trust. These final clinical trials confirm the data we have observed in previous explorative studies and provide evidence that intramuscular vaccination with Strangvac® provides good protection against strangles.